REPORT ID 2351

United States Ulcerative Colitis Immunology Drugs Market Report 2019

Publish Date
2019
Pages
99
Format
Electronic (PDF)

In this report, the United States Ulcerative Colitis Immunology Drugs market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report splits the United States market into seven regions:
    The West
    Southwest
    The Middle Atlantic
    New England
    The South
    The Midwest
with sales (volume), revenue (value), market share and growth rate of Ulcerative Colitis Immunology Drugs in these regions, from   2019 to 2025 (forecast).

United States Ulcerative Colitis Immunology Drugs market competition by top manufacturers/players, with Ulcerative Colitis Immunology Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
    Janssen Biotech, Inc.
    Bristol-Myers Squibb Company
    AbbVie Inc.
    UCBCares
    AMGEN
    Celltrion Healthcare
    Biogen
    Genentech USA, Inc.
    ROCHE
    Pfizer Inc.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Adalimumab
    Certolizumab Pegol
    Tofacitinib
    Etanercept
    Golimumab
    Abatacept
    Infliximab
    Others
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Rheumatoid Arthritis
    Crohn's Disease(CD)
    Ankylosing Spondylitis(AS)
    Psoriasis(Ps)
    Ulcerative Colitis(UC)

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

United States Ulcerative Colitis Immunology Drugs Market  Report 2019
1 Ulcerative Colitis Immunology Drugs Overview
    1.1 Product Overview and Scope of Ulcerative Colitis Immunology Drugs
    1.2 Classification of Ulcerative Colitis Immunology Drugs by Product Category
        1.2.1 United States Ulcerative Colitis Immunology Drugs Market Size (Sales Volume) Comparison by Type ( 2014-2024)
        1.2.2 United States Ulcerative Colitis Immunology Drugs Market Size (Sales Volume) Market Share by Type (Product Category)  in 2018
        1.2.3 Adalimumab
        1.2.4 Certolizumab Pegol
        1.2.5 Tofacitinib
        1.2.6 Etanercept
        1.2.7 Golimumab
        1.2.8 Abatacept
        1.2.9 Infliximab
        1.2.10 Others
    1.3 United States Ulcerative Colitis Immunology Drugs Market by Application/End Users
        1.3.1 United States Ulcerative Colitis Immunology Drugs Market Size (Consumption) and Market Share Comparison by Application ( 2014-2024)
        1.3.2 Rheumatoid Arthritis
        1.3.3 Crohn's Disease(CD)
        1.3.4 Ankylosing Spondylitis(AS)
        1.3.5 Psoriasis(Ps)
        1.3.6 Ulcerative Colitis(UC)
    1.4 United States Ulcerative Colitis Immunology Drugs Market by Region
        1.4.1 United States Ulcerative Colitis Immunology Drugs Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 The West Ulcerative Colitis Immunology Drugs Status and Prospect ( 2014-2024)
        1.4.3 Southwest Ulcerative Colitis Immunology Drugs Status and Prospect ( 2014-2024)
        1.4.4 The Middle Atlantic Ulcerative Colitis Immunology Drugs Status and Prospect ( 2014-2024)
        1.4.5 New England Ulcerative Colitis Immunology Drugs Status and Prospect ( 2014-2024)
        1.4.6 The South Ulcerative Colitis Immunology Drugs Status and Prospect ( 2014-2024)
        1.4.7 The Midwest Ulcerative Colitis Immunology Drugs Status and Prospect ( 2014-2024)
    1.5 United States Market Size (Value and Volume) of Ulcerative Colitis Immunology Drugs ( 2014-2024)
        1.5.1 United States Ulcerative Colitis Immunology Drugs Sales and Growth Rate ( 2014-2024)
        1.5.2 United States Ulcerative Colitis Immunology Drugs Revenue and Growth Rate ( 2014-2024)

2 United States Ulcerative Colitis Immunology Drugs Market Competition by Players/Suppliers
    2.1 United States Ulcerative Colitis Immunology Drugs Sales and Market Share of Key Players/Suppliers ( 2014-2019)
    2.2 United States Ulcerative Colitis Immunology Drugs Revenue and Share by Players/Suppliers ( 2014-2019)
    2.3 United States Ulcerative Colitis Immunology Drugs Average Price by Players/Suppliers ( 2014-2019)
    2.4 United States Ulcerative Colitis Immunology Drugs Market Competitive Situation and Trends
        2.4.1 United States Ulcerative Colitis Immunology Drugs Market Concentration Rate
        2.4.2 United States Ulcerative Colitis Immunology Drugs Market Share of Top 3 and Top 5 Players/Suppliers
        2.4.3 Mergers & Acquisitions, Expansion in United States Market
    2.5 United States Players/Suppliers Ulcerative Colitis Immunology Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Ulcerative Colitis Immunology Drugs Sales (Volume) and Revenue (Value) by Region ( 2014-2019)
    3.1 United States Ulcerative Colitis Immunology Drugs Sales and Market Share by Region ( 2014-2019)
    3.2 United States Ulcerative Colitis Immunology Drugs Revenue and Market Share by Region ( 2014-2019)
    3.3 United States Ulcerative Colitis Immunology Drugs Price by Region ( 2014-2019)

4 United States Ulcerative Colitis Immunology Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) ( 2014-2019)
    4.1 United States Ulcerative Colitis Immunology Drugs Sales and Market Share by Type (Product Category) ( 2014-2019)
    4.2 United States Ulcerative Colitis Immunology Drugs Revenue and Market Share by Type ( 2014-2019)
    4.3 United States Ulcerative Colitis Immunology Drugs Price by Type ( 2014-2019)
    4.4 United States Ulcerative Colitis Immunology Drugs Sales Growth Rate by Type ( 2014-2019)

5 United States Ulcerative Colitis Immunology Drugs Sales (Volume) by Application ( 2014-2019)
    5.1 United States Ulcerative Colitis Immunology Drugs Sales and Market Share by Application ( 2014-2019)
    5.2 United States Ulcerative Colitis Immunology Drugs Sales Growth Rate by Application ( 2014-2019)
    5.3 Market Drivers and Opportunities

6  United States Ulcerative Colitis Immunology Drugs Players/Suppliers Profiles and Sales Data
    6.1 Janssen Biotech, Inc.
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Bristol-Myers Squibb Company
        6.2.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 AbbVie Inc.
        6.3.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 UCBCares
        6.4.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 AMGEN
        6.5.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Celltrion Healthcare
        6.6.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Biogen
        6.7.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Genentech USA, Inc.
        6.8.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 ROCHE
        6.9.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 Pfizer Inc.
        6.10.2 Ulcerative Colitis Immunology Drugs Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview

7 Ulcerative Colitis Immunology Drugs Manufacturing Cost Analysis
    7.1 Ulcerative Colitis Immunology Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Ulcerative Colitis Immunology Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Ulcerative Colitis Immunology Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Ulcerative Colitis Immunology Drugs Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 United States Ulcerative Colitis Immunology Drugs Market Size (Value and Volume) Forecast ( 2019-2025)
    11.1 United States Ulcerative Colitis Immunology Drugs Sales Volume, Revenue Forecast ( 2019-2025)
    11.2 United States Ulcerative Colitis Immunology Drugs Sales Volume Forecast by Type ( 2019-2025)
    11.3 United States Ulcerative Colitis Immunology Drugs Sales Volume Forecast by Application ( 2019-2025)
    11.4 United States Ulcerative Colitis Immunology Drugs Sales Volume Forecast by Region ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer